2 Result: Immunovant
BlackRock Posts Mixed Q3 Earnings; Bullish View On Immunovant
October 13th, 2023
BlackRock, Inc. (NYSE: BLK), an investment management and financial services company, reported third-quarter 2023 adjusted earnings per share (EPS) of $10.91, surpassing the consensus EPS estimate of $8.26. However, the company's revenue for the peri. Read more
Immunovant's IMVT-1402 Data Sparks Momentum; Ferguson Outperforms Estimates
September 26th, 2023
Shares of Immunovant, Inc. (Nasdaq: IMVT) surged by more than 40% in pre-market trading after promising Phase 1 trial results for IMVT-1402. Administered subcutaneously in healthy adults, IMVT-1402 demonstrated significant dose-dependent reductions i. Read more
Want To Find Some News?
News By Industries
Recent Post
-
Key Earnings Ahead for Netflix, Fastenal, and U.S. Bancorp
January 18th, 2026Louisville Thunder Appoints Veteran Coach Mike Reed to Lead Program
January 15th, 2026FDA Approves First Treatment for Children With Menkes Disease
January 13th, 2026January 13th, 2026Wall Street Eyes Bank of America, Wells Fargo, Citi Ahead of Earnings
January 11th, 2026
Member Login